- ISIN
- US92731L1061
- CUSIP
- 92731L106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 27, 2020
Highlights
- Market Cap
- $66.48K
- Total Revenue (TTM)
- $1.07M
- Gross Profit (TTM)
- $264.00K
- EBITDA (TTM)
- -$26.49M
- Year Range
- $0.00 - $0.07
- Avg. Volume (1M)
- 5K
- Avg. Volume Value (1M)
- $61.75
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
VINC Performance Chart
Vincerx Pharma, Inc. (VINC) is up 1.6% since the beginning of the year. At $0 per share, VINC is trading 82.8% below its 52-week high of $0. Investors who bought $1,000 worth of VINC shares 5 years ago would now be looking at an investment worth $0.
Loading charts...
Compare this symbol against anything
Returns By Period
Vincerx Pharma, Inc. (VINC) has returned 1.60% so far this year and -64.82% over the past 12 months.
Vincerx Pharma, Inc.
- 1D
- 0.00%
- 1M
- 0.00%
- 6M
- -0.39%
- YTD
- 1.60%
- 1Y
- -64.82%
- 3Y*
- -91.46%
- 5Y*
- -86.32%
- 10Y*
- —
- ALL TIME*
- -78.86%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
VINC Monthly Returns History
Based on dividend-adjusted daily data since May 27, 2020, VINC's average daily return is -0.23%, while the average monthly return is -2.68%.
Historically, 37% of months were positive and 63% were negative. The best month was Feb 2024 with a return of +186.3%, while the worst month was Apr 2025 at -90.1%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 12 months.
On a daily basis, VINC closed higher 40% of trading days. The best single day was Nov 17, 2025 with a return of +98.0%, while the worst single day was Oct 30, 2025 at -84.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.00% | -0.00% | 0.78% | -1.17% | -0.00% | -0.00% | 0.00% | 1.60% | |||||
| 2025 | -69.94% | -31.01% | -51.43% | -90.08% | -7.62% | -9.28% | -9.77% | -18.14% | 35.38% | -87.50% | 120.00% | 3.31% | -99.76% |
| 2024 | 11.02% | 186.26% | 34.93% | -83.66% | -23.70% | 28.37% | -21.31% | 28.65% | -12.68% | -51.26% | -18.34% | -7.79% | -77.73% |
| 2023 | 48.04% | -23.18% | -10.34% | 25.96% | 41.22% | -29.73% | -16.92% | -38.89% | 53.03% | -8.46% | -29.70% | 81.54% | 15.69% |
| 2022 | -29.44% | -29.49% | -21.10% | -35.50% | -36.82% | -19.02% | 6.06% | 8.57% | -9.21% | -22.46% | -34.58% | 45.71% | -89.99% |
| 2021 | -8.70% | 1.10% | -0.00% | -17.10% | -13.25% | -6.41% | 2.00% | 18.34% | 3.12% | -13.61% | -24.91% | -2.86% | -51.27% |
Benchmark Metrics
Vincerx Pharma, Inc. has an annualized alpha of -46.04%, beta of 0.27, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since May 27, 2020.
- This stock participated in 278.25% of S&P 500 Index downside but only -73.40% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.27 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -46.04%
- Beta
- 0.27
- R²
- 0.00
- Upside Capture
- -73.40%
- Downside Capture
- 278.25%
Return for Risk
Risk / Return Rank
VINC ranks 38 for risk / return — above 38% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Vincerx Pharma, Inc. (VINC) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VINC | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.79 | ||
| Sortino ratioReturn per unit of downside risk | -1.15 | ||
| Omega ratioGain probability vs. loss probability | 1.20 | 1.25 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | -0.74 | 2.00 | -2.74 |
| Martin ratioReturn relative to average drawdown | -0.94 | 8.49 | -9.43 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Vincerx Pharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Vincerx Pharma, Inc. was 100.00%, occurring on Oct 30, 2025. The portfolio has not yet recovered.
The current Vincerx Pharma, Inc. drawdown is 100.00%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-100.00%Oct 2025 | 4y 7mo | — | 5y 4moMar 2021 - now | — |
-22.70%Feb 2021 | 22d | 28d | 1mo 20dJan 2021 - Mar 2021 | — |
-10.10%Jun 2020 | 1d | 3mo 29d | 3mo 29dJun 2020 - Sep 2020 | — |
-9.42%Dec 2020 | 16d | 11d | 27dNov 2020 - Dec 2020 | — |
-7.38%Jan 2021 | 1d | 8d | 9dJan 2021 - Jan 2021 | — |
Drawdown Indicators
| VINC | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -92.42% | -9.10% | -83.32% |
Max Drawdown (3Y)Largest decline over 3 years | -100.00% | -18.90% | -81.10% |
Max Drawdown (5Y)Largest decline over 5 years | -100.00% | -25.43% | -74.57% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -100.00% | -1.58% | -98.42% |
Average DrawdownAverage peak-to-trough decline | -77.13% | -10.70% | -66.43% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 72.37% | 2.14% | +70.23% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Vincerx Pharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Vincerx Pharma, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with VINC
Add Vincerx Pharma, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with VINC